Millie
your market intelligence analyst
Search Results
162 results
Your search is now limited to «Biomarkers» expert search.
GlobeNewswire 08/13/2020 06:30
Furthermore, as the ability to achieve early detection of AD develops, based on the advent of reliable blood-based biomarkers for AD detection, the need for preventive treatment will grow.
More from GlobeNewswire:
PharmiWeb.com 08/13/2020 01:43
Pune, Maharashtra, India, August 13 2020 (Wiredrelease) MarketResearch.Biz –: The recent report posted via MarketResearch.Biz on Neurological Biomarkers market offers critical market insights in conjunction with targeted segmentation evaluation. The report examines key using elements which might be anticipated to drive the increase of the market. Global Neurological Biomarkers Market Research Report offers crucial data on numerous market situations, for example, ability improvement elements,...
More from PharmiWeb.com:
Lancet 08/13/2020 00:40
The number of older people, including those living with dementia, is rising, as younger age mortality declines. However, the age-specific incidence of dementia has fallen in many countries, probably because of improvements in education, nutrition, health care, and lifestyle changes. Overall, a growing body of evidence supports the nine potentially modifiable risk factors for dementia modelled by the 2017 Lancet Commission on dementia prevention, intervention, and care: less education, hypertension, hearing impairment, smoking, obesity, depression, physical inactivity, diabetes, and low social contact.
More from Lancet:
Early data suggests that CT1812 and AL001 shift biomarker levels in Alzheimer’s disease and frontotemporal dementia, respectively. BI 425809 fails to improve cognition.
More from Alzheimer's Research & Therapy:
News-Medical.net 08/12/2020 09:50
... future diagnoses and treatments of Alzheimer’s disease utilizing a wide variety of assays and techniques from basic applications, such as quantitative measurement of stable-isotope labeled peptides to clinical translational studies in diagnostic and therapeutic biomarkers for Alzheimer’s disease.
More from News-Medical.net:
EurekAlert 08/11/2020
Scientists from the Daegu Gyeongbuk Institute of Science and Technology, Republic of Korea, discover a new way to diagnose Alzheimer's disease by analyzing the levels of specific proteins in nasal discharge. This simple and inexpensive method could help in timely diagnosis of Alzheimer's disease, in order to start treatment as soon as possible, thus delaying disease progression.
More from EurekAlert:
Seeking Alpha 08/09/2020 13:38
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q3 2020 Results Conference Call August 06, 2020 11:00 AM ET Company Participants Clint Tomlinson - IR Dr.
More from Seeking Alpha:
Alzforum News 08/08/2020 16:45
Other researchers brought imaging and fluid biomarkers of synaptic integrity into the growing AD biomarker toolkit, with the hopes of more accurately predicting cognitive decline.
More from Alzforum News:
PubMed News (NIH) 08/05/2020
Contributors : Marcos Otero-Garcia ; Yueqiang Xue ; Tamara Shakouri ; Yongning Deng ; Samuel Morabito ; Riki Kawaguchi ; Vivek Swarup ; Inma Cobos Series Type : Expression profiling by high throughput sequencing Organism : Homo sapiens. Aggregation of hyperphosphorylated tau in neurofibrillary tangles (NFTs) is closely associated with neuronal death and the progression of cognitive deficits in Alzheimer’s disease (AD).
Business Wire 08/04/2020 16:29
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation today announced financial results for the three months ending June 30, 2020.
More from Business Wire:
LabOnline (Australia) 08/02/2020 10:00
Alzheimer’s disease is characterised by the presence of plaques in the brain formed by a protein called amyloid-β, as well as aggregates of a protein called tau that form neurofibrillary tangles in the neurons of Alzheimer’s patients. Amyloid-β and tau start to change years before any cognitive symptoms, such as memory loss and confusion, become apparent, but previously the only way to detect them was with a positron emission tomography (PET) scan to visualise the brain, or a spinal tap to measure changing levels of amyloid-β and tau in cerebrospinal fluid. These methods are expensive, invasive and often unavailable because they are not covered by insurance and/or difficult to access. “There is an urgent need for simple, inexpensive, non-in.
More from LabOnline (Australia):

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications